Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously untreated symptomatic chronic lymphocytic leukemia (CLL). A phase II FILO trial

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521199-80-00

Acronym

FILOCLL016-PACIFIC

Enrollment

Registered

2025-11-05

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with previously untreated symptomatic chronic lymphocytic leukemia.

Brief summary

Peripheral blood with undetectable (<10-4) minimal residual disease at month 24.

Detailed description

PB MRD at month 9 and 18 and BM MRD at month 24, Progression free survival (PFS), disease-free survival (DFS), event-free survival (EFS), overall survival (OS) and time to next treatment (TTNT)

Interventions

DRUGPIRTOBRUTINIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Peripheral blood with undetectable (<10-4) minimal residual disease at month 24.	—

Secondary

Measure	Time frame
PB MRD at month 9 and 18 and BM MRD at month 24, Progression free survival (PFS), disease-free survival (DFS), event-free survival (EFS), overall survival (OS) and time to next treatment (TTNT)	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026